Study to Examine if Blood Test Can Detect Cancer Early in Low-Risk Women

Study to Examine if Blood Test Can Detect Cancer Early in Low-Risk Women
The University of Texas’ MD Anderson Cancer Center, in collaboration with the National Cancer Institute and Golfers Against Cancer, is evaluating the usefulness of a blood test called CA-125 at detecting ovarian cancer at early stages in low-risk women. Cancer antigen 125 (CA-125) is a protein found at higher levels in people with ovarian and other types of cancer. The CA-125 test is frequently used to detect ovarian cancer in women at high risk for the disease, and to monitor treatment response or disease relapse in ovarian cancer patients. Because high CA-125 levels can be a sign of other conditions besides ovarian cancer, the test is usually not used to screen women at low risk for the disease. Sponsored by MD Anderson, the CA-125 study (NCT00539162) will assess whether this blood test may be helpful for early detection of ovarian cancer in low-risk women, who would not normally be screened for it. “Ovarian cancer accounts for more deaths than any other gynecologic cancer,” Daniel Tobias, MD, the medical director of
Subscribe or to access all post and page content.